The impact of hormonal status on 18FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT. | ||
| Egyptian Journal of Chemistry | ||
| Volume 66, Issue 5, May 2023, Pages 331-339 PDF (473.55 K) | ||
| Document Type: Review Articles | ||
| DOI: 10.21608/ejchem.2022.156309.6763 | ||
| Authors | ||
| Ahmed Nasr El Sayed* 1; Hosna Moustafa2; Gamal Abd El metal3; Ahmed Tawakol4 | ||
| 1Nuclear Medicine Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt | ||
| 2Oncology and Nuclear Medicine Department (NEMROCK), Kasr-El-Ainy Hospital, Cairo University, Egypt | ||
| 3Medical Oncology department At Maadi Armed Forces Medical Compound Kasr-El-Ainy Hospital, Cairo University, Egypt | ||
| 4Oncology and Nuclear Medicine Department (NEMROCK), Kasr -El-Ainy Hospital, Cairo University, Egypt | ||
| Abstract | ||
| Introduction FDG PET/CT whole-body imaging has higher sensitivity, specificity and accuracy as compared to CT in detection of metastatic spread and follows up after treatment. The aim of this study: to assess of the impact of PET/CT in patients with metastatic breast cancer and monitoring the therapy response in relation to different molecular subtypes. Material and Methods: The study included 40 patients classified into 4 molecular subtypes; Luminal A like subtype (13 patients), Luminal B+ subtype (15 patients), Luminal B- subtype (4 patients) and Basal like subtype (8 patients). All patients with possible metastatic breast cancer performed PET-CT before treatment, while 34 patients perform PET-CT after the end of therapy. Results: on lesion based analysis the total numbers of metastatic lesions in CT and bone scan were 120 lesions (49 in LNs, 24 in lung, 8 in liver; while 39 in bone). Metastatic lesions in PET/CT were 98 lesions (46 in LNs, 22 in lung and 8 in liver and 22 in bone). During follow up after therapy, the majority of luminal A group showed complete response to therapy to therapy in PET/CT scan PET/CT scan. Also, luminal B+ subgroup showed partial response. While most of basal-like subgroup showed progressive disease. Conclusion: PET/CT can detect metastatic spread in breast cancer and monitor therapy response in relation to different molecular subtypes. The mean SUV max showed relation to the different molecular subtypes. | ||
| Keywords | ||
| Key Words: PET/CT; Molecular Subtypes and Metastatic Lesions | ||
|
Statistics Article View: 133 PDF Download: 85 |
||
